Startpage Heidelberg University Hospital Startpage Heidelberg University Hospital
Department of… Research Neuroimmunology Molecular… MOG…

MOG ENCEPHALOMYELITIS

Diagnostic and pathophysiological relevance of autoantibodies to myelin oligodendrocyte glycoprotein (MOG-IgG)

 

Principal investigators: Sven Jarius, Brigitte Wildemann 

 

MOG encephalomyelitis (MOG-EM) is an inflammatory, demyelinating disorder of the central nervous system. The phenoytpical spectrum of MOG-EM includes mainly optic neuritis, myelitis and/or brainstem encephalitis as well as ADEM- and MS-like manifestations. In most cases, the disease takes a relapsing course. Our work focuses on investigating the diagnostic, prognostic, und pathophysiological relevance of antibodies to myelin oligodendrocyte glycoprotein (MOG-IgG) in patients with demyelinating disorders of the central nervous system (multiple sclerosis, neuromyelitis optica, transverse myelitis, optic neuritis, brainstem encephalitis) and on developing and establishing new, recombinant assays for the detection of MOG-IgG.

 

Independent projects are dedicated to investigating the pathophysiological and diagnostic relevance of autoantibodies in other inflammatory diseases of the central and peripheral nervous system (e.g., neuromyelitis optica spectrum disorder, paraneoplastic and non-paraneoplastic cerebellar ataxia, limbic encephalitis, peripheral neuropathy, Susac syndrome; see here and here).

 

Email-Adressen für Anfragen: 

sven.jarius(at)med.uni-heidelberg.de

brigitte.wildemann(at)med.uni-heidelberg.de

 

Selected publications

  • Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B. MOG-Enzephalomyelitis: Empfehlungen zu Diagnose und Antikörpertestung. Nervenarzt 2018; in press.
  • Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 2018 May 3;15(1):134. [FREE PDF]
  • Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume L, Hümmert MW, Trebst C, Ringelstein M, Aktas O, Winkelmann A, Buttmann M, Schwarz A, Zimmermann H, Brandt AU, Franciotta D, Capobianco M, Kuchling J, Haas J, Korporal-Kuhnke M, Lillevang ST, Fechner K, Schanda K, Paul F*, Wildemann B*, Reindl M*. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 2016 Okt 26;13(1):279. [FREE PDF]
  • Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume L, Hümmert MW, Ringelstein M, Trebst C, Winkelmann A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F*, Reindl M*, Wildemann B*. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment, and long-term outcome. J Neuroinflammation 2016 Okt 27;13(1):280. [FREE PDF]
  • Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N, Hümmert MW, Trebst C, Pache F, Winkelmann A, Beume LA, Ringelstein M, Stich O, Aktas O, Korporal-Kuhnke M, Schwarz A, Lukas C, Haas J, Fechner K, Buttmann M, Bellmann-Strobl J, Zimmermann H, Brandt AU, Franciotta D, Schanda K, Paul F*, Reindl M*, Wildemann B*. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement – frequency, presentation and outcome. J Neuroinflammation 2016 Nov 1;13:281. [FREE PDF]
  • Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, Bellmann-Strobel J, Jarius S, Wildemann B, Reindl M, Waldman A, Soelberg K, Nasrin Asgari, Ringelstein M, Aktas O, Gross N, Buttmann M, Ach T, Ruprecht K, Paul F, Brandt AU. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation 2016 Nov 1;13:282. [FREE PDF]
  • Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, Lutterotti A, Jarius S, Di Pauli F, Kuenz B, Ehling R, Hegen H, Deisenhammer F, Aboul-Enein F, Storch MK, Koson P, Drulovic J, Kristoferitsch W, Berger T, Reindl M. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011 Dec 28;8:184 [FREE PDF]
  • Reindl M, Jarius S, Rostasy K, Berger T. Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they? Curr Opin Neurol 2017 Jun;30(3):295-301.
  • Wildemann B, Jarius S, Schwarz A, Diem R, Viehöver A, Hähnel S, Reindl M, Korporal-Kuhnke M. Failure of alemtuzumab therapy to control MOG encephalomyelitis. Neurology 2017 Jul 11;89(2):207-209.
  • Bouzar M, Daoudi S, Hattab S, Bouzar AA, Deiva K, Wildemann B, Reindl M, Jarius S. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: clinical and paraclinical characteristics in Algerian patients. J Neurol Sci 2017 Sep;381:240-244 [FREE PDF].
  • Soelberg K, Jarius S, Skejø HBP, Engberg H, Mehlsen JJ, Nielsson AC, Madsen JS, Reindl M, Wildemann B, Grauslund J, Kyvik KO, Smith TJ, Lillevang ST, Paul F, Weinshenker BG, Asgari N. A population-based prospective study of optic neuritis. Mult Scler 2017 Dec;23(14):1893-1901.
  • Soelberg K, Skejoe HPB, Grauslund J, Smith TJ, Lillevang ST, Jarius S, Wildemann B, Paul F, Asgari N. Magnetic resonance imaging findings at the first episode of acute optic neuritis. Mult Scler Relat Disord 2018; epub ahead of print (https://doi.org/10.1016/j.msard.2017.12.018).
  • Jarius S, Metz I, König F, Ruprecht K, Reindl M, Paul F, Brück W, Wildemann B. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case. Mult Scler 2016 Oct;22(12):1541-1549.
  • Soelberg K, Nilsson AC, Nielsen C, Jarius S, Reindl M, Wildemann B, Lillevang ST, Asgari N. Autoimmune and immunogenetic profile of MOG-IgG-positive and MOG-IgG-negative patients with optic neuritis in a population-based cohort. Mult Scler Relat Disord. 2018 Mar 7;21:97-102.
  • Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, Willing A, Trebst C, Pawlitzki M, Abdelhak A, Grüter T, Leypoldt F, Haas J, Kleiter I, Tumani H, Fechner K, Reindl M, Paul F, Wildemann B. MOG-IgG in primary and secondary chronic progressive multiple sclerosis:  a multicenter study of 200 patients and review of the literature. J Neuroinflammation 2018 Mar 19;15(1):88 [FREE PDF].